CeriBell, Inc.
Moat Score — CeriBell, Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Ceribell's FDA-cleared Clarity AI seizure-detection algorithm and its point-of-care EEG hardware represent genuine, patent-protected proprietary technology addressing an underserved clinical workflow gap. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | The disposable-headband, razor-and-blade business model drives 87% gross margins, a structurally favorable cost position versus alternatives that require expensive technician time and full EEG setups. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | High and improving gross margins alongside new CMS NTAP reimbursement approval for its Delirium Monitor System indicate Ceribell can command premium, reimbursement-backed pricing for its platform. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Broader hospital adoption generates more clinical data that can improve the Clarity algorithm over time, a mild data-network effect rather than a strong direct network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once emergency department and ICU staff are trained on the Ceribell workflow and it is integrated into clinical protocols and reimbursement coding, switching back to traditional EEG or to a competing device carries real retraining and workflow-disruption costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | As an early mover in FDA-cleared, reimbursement-backed point-of-care EEG, Ceribell has a head start that a new entrant would need years of clinical trials and payer negotiations to replicate, though larger device makers could eventually target the same niche. |